Gut Molecule Linked to Decreased Myelination in Mouse Brains
How it’s doing it, we still need to understand.”
Mazmanian and his colleagues engineered two strains of bacteria to produce enzymes that convert the amino acid tyrosine to 4EP in large amounts. Germ-free mice—which lack a gut microbiome—fed these bioengineered bacteria had high blood levels of 4EPS and altered behaviors. Compared with control mice, which were fed bacteria without the engineered enzymes, they showed increased anxiety-like behaviors, atypical social behaviors and fewer ultrasonic vocalizations.
Both groups of mice performed similarly on cognitive tasks, however, suggesting that the effects of increased 4EPS are limited to emotional behaviors. In line with that idea, mice with high levels of 4EPS had unusual connectivity patterns in brain regions related to emotion processing, functional ultrasound images showed.
At the cellular level, the animals have immature oligodendrocytes, brain cells that produce myelin. They also have low levels of myelination throughout the brain, which could explain the connectivity changes, the researchers say.
Treating 4EPS mice with the drug clemastine fumarate, which encourages oligodendrocytes to mature, prevented the increased anxiety behaviors in the animals, the researchers found.
“What that tells us is that the arrest in oligodendrocyte maturation is critical for the changes in behavior,” Mazmanian says.
company that Mazmanian co-founded and directs, is conducting a clinical trial of an experimental drug, AB-2004, that could sop up 4EP throughout the gastrointestinal tract, with the goal of treating irritability in autistic children. Giving AB-2004 to mice with high levels of 4EPS lowers those levels and lessens the animals’ anxiety-like behaviors, the team found in a study in Nature Medicine, also published today.
The drug was safe and well-tolerated in 26 autistic adolescents, the new study shows, and preliminary evidence suggests that it lowered 4EPS levels and lessened anxiety and irritability in the participants. But because the trial was designed only to assess safety, it had no control group. It was also open-label, meaning that participants and their caregivers knew they were receiving the drug, increasing the chances of a placebo effect.
https://www.spectrumnews.org/news/gut-molecule-linked-to-decreased-myelination-in-mouse-brains/